Resveratrol

501-36-0

228.24

DMSO : 100 mg/mL (438.14 mM; Need ultrasonic)

Anti-infection; Apoptosis; Anti-infection; Autophagy; Epigenetics; Cell Cycle/DNA Damage; NF-kappaB; NF-kappaB; Autophagy; Anti-infection

Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, beta-amyloid, Adenylyl cyclase, IKKbeta, DNA polymerase. Resveratrol also is a specific SIRT1 activator. Resveratrol is a potent pregnane X receptor (PXR) inhibitor. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model. Resveratrol increases production of NO in endothelial cells.
IC50 & Target: IC50: 0.8 uM (Adenylyl cyclase), 1 uM (IKKbeta), 3.3 and 5 uM (DNA polymerase alpha and delta)
In Vitro: Resveratrol (trans-Resveratrol; SRT501) is one of the numerous polyphenolic compounds found in several vegetal sources In the vast majority of cases, Resveratrol displays inhibitory/activatory effects in the micromolar range, which is potentially attainable pharmacologically, although targets with affinities in the nanomolar range have also been reported.

MCF-7 cells are plated in DME-F12 medium supplemented with 5% FBS in the presence of increasing concentrations of Resveratrol. Control cells are treated with the same volume of vehicle only (0.1% ethanol). Resveratrol inhibits the growth of MCF-7 cells in a dose-dependent fashion. Addition of 10 uM Resveratrol results in an 82% inhibition of MCF-7 cell growth after 6 days while at 1 uM, only a 10% inhibition is observed. The cells treated with 10 uM Resveratrol have a doubling time of 60 hr whereas control cells doubled every 30 hr. Trypan blue exclusion assay shows that at concentrations of 10 uM or lower, Resveratrol does not affect cell viability (90% viable cells) whereas at 100 uM, only 50% of the cells are viable after 6 days of Resveratrol treatment. Moreover, MCF-7 cells do not undergo apoptosis after incubation with Resveratrol at concentration of 10 uM as determined by ApoAlert Annexin V Apoptosis kit.

Resveratrol increases the production of nitric oxide (NO) in endothelial cells by upregulating the expression of endothelial NO synthase (eNOS), stimulating eNOS enzymatic activity, and preventing eNOS uncoupling.
In Vivo: The average tumor volume is reduced by treatment with Resveratrol (trans-Resveratrol; SRT501) at a dose of 50 mg/kg body weight (195.5+/-124.8 mm3; P<0.05) or 100 mg/kg body weight (81.7+/-70.5 mm3; P<0.001) compare with the vehicle-treated animals (315+/-94 mm3). There is a good correlation between the tumor volume and the tumor mass.